Advancements in Treatment for Uterine Cancer

June is Uterine Cancer Awareness Month, and while awareness often focuses on symptoms and early detection, it’s also important to highlight something encouraging: treatment for uterine cancer is changing.

According to a 2026 PubMed-indexed review, endometrial cancer therapy has improved in ways that are increasing survival and outcomes, especially through immunotherapy, molecular testing, and more personalized treatment approaches. (PubMed)

For many years, treatment for advanced or recurrent endometrial cancer relied heavily on surgery, chemotherapy, and radiation. Those options still matter, but the field has moved toward therapies that better match the biology of each person’s cancer.

One major advancement is immunotherapy, which helps the immune system recognize and attack cancer cells. In 2024, the FDA approved pembrolizumab with carboplatin and paclitaxel, followed by pembrolizumab alone, for adults with primary advanced or recurrent endometrial carcinoma. (U.S. Food and Drug Administration) The FDA also expanded approval of dostarlimab with chemotherapy, followed by dostarlimab alone, for adults with primary advanced or recurrent endometrial cancer. (U.S. Food and Drug Administration)

These approvals are significant because they bring immunotherapy earlier into treatment for more patients, rather than reserving it only for later lines of care.

Another important shift is molecular testing. Doctors can now look for features such as mismatch repair deficiency, microsatellite instability, hormone receptor status, and other tumor markers. These clues help guide treatment decisions and may open doors to immunotherapy, hormone-based treatment, targeted therapy, or clinical trials.

Researchers are also studying hormonal therapy combinations, antibody-drug conjugates, and other targeted treatments. A 2024 review of top uterine cancer advances noted meaningful progress in immunotherapy, hormonal approaches, antibody-drug conjugates, and other targeted therapies. (Experts@Minnesota)

For patients and families, this progress matters. It means uterine cancer care is becoming more precise, more individualized, and more hopeful.

This month, we honor everyone affected by uterine cancer: those newly diagnosed, those in treatment, those living with recurrence, and those supporting someone they love.

Science is moving forward. Options are expanding. And every advancement brings the uterine cancer community one step closer to better outcomes. 💛